文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

胰腺癌肿瘤微环境是一个主要的治疗障碍和靶点。

Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.

机构信息

Division of Surgical Oncology, Department of Surgery, Louisiana State University (LSU) Health, New Orleans, LA, United States.

Department of Pathology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR, United States.

出版信息

Front Immunol. 2024 Feb 1;15:1287459. doi: 10.3389/fimmu.2024.1287459. eCollection 2024.


DOI:10.3389/fimmu.2024.1287459
PMID:38361931
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10867137/
Abstract

Pancreatic Ductal Adenocarcinoma (PDAC) is projected to become the 2nd leading cause of cancer-related deaths in the United States. Limitations in early detection and treatment barriers contribute to the lack of substantial success in the treatment of this challenging-to-treat malignancy. Desmoplasia is the hallmark of PDAC microenvironment that creates a physical and immunologic barrier. Stromal support cells and immunomodulatory cells face aberrant signaling by pancreatic cancer cells that shifts the complex balance of proper repair mechanisms into a state of dysregulation. The product of this dysregulation is the desmoplastic environment that encases the malignant cells leading to a dense, hypoxic environment that promotes further tumorigenesis, provides innate systemic resistance, and suppresses anti-tumor immune invasion. This desmoplastic environment combined with the immunoregulatory events that allow it to persist serve as the primary focus of this review. The physical barrier and immune counterbalance in the tumor microenvironment (TME) make PDAC an immunologically cold tumor. To convert PDAC into an immunologically hot tumor, tumor microenvironment could be considered alongside the tumor cells. We discuss the complex network of microenvironment molecular and cellular composition and explore how they can be targeted to overcome immuno-therapeutic challenges.

摘要

胰腺导管腺癌 (PDAC) 预计将成为美国癌症相关死亡的第二大主要原因。早期检测的局限性和治疗障碍导致这种难以治疗的恶性肿瘤的治疗效果缺乏实质性的成功。间质是 PDAC 微环境的标志,它形成了物理和免疫屏障。基质支持细胞和免疫调节细胞受到胰腺癌细胞异常信号的影响,使适当的修复机制的复杂平衡转变为失调状态。这种失调的产物是包裹恶性细胞的间质环境,导致密集、缺氧的环境,促进进一步的肿瘤发生,提供先天的全身耐药性,并抑制抗肿瘤免疫浸润。这种间质环境与允许其持续存在的免疫调节事件一起,构成了本综述的主要焦点。肿瘤微环境 (TME) 中的物理屏障和免疫平衡使 PDAC 成为一种免疫冷肿瘤。为了将 PDAC 转化为免疫热肿瘤,可以将肿瘤微环境与肿瘤细胞一起考虑。我们讨论了微环境分子和细胞组成的复杂网络,并探讨了如何针对这些网络来克服免疫治疗挑战。

相似文献

[1]
Pancreatic cancer tumor microenvironment is a major therapeutic barrier and target.

Front Immunol. 2024

[2]
Focus on Pancreatic Cancer Microenvironment.

Curr Oncol. 2024-7-26

[3]
Innate and adaptive immune-directed tumour microenvironment in pancreatic ductal adenocarcinoma.

Front Immunol. 2024

[4]
Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options.

Front Immunol. 2018-8-15

[5]
The Role of Tumor Microenvironment in Pancreatic Cancer Immunotherapy: Current Status and Future Perspectives.

Int J Mol Sci. 2024-9-3

[6]
The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment.

Am J Pathol. 2019-1

[7]
Persistent activation of pancreatic stellate cells creates a microenvironment favorable for the malignant behavior of pancreatic ductal adenocarcinoma.

Int J Cancer. 2012-10-5

[8]
Panoramic tumor microenvironment in pancreatic ductal adenocarcinoma.

Cell Oncol (Dordr). 2024-10

[9]
The critical roles of activated stellate cells-mediated paracrine signaling, metabolism and onco-immunology in pancreatic ductal adenocarcinoma.

Mol Cancer. 2018-2-19

[10]
Immune Cell Modulation of the Extracellular Matrix Contributes to the Pathogenesis of Pancreatic Cancer.

Biomolecules. 2021-6-17

引用本文的文献

[1]
Perineural invasion and the "cold" tumor microenvironment in pancreatic cancer: mechanisms of crosstalk and therapeutic opportunities.

Front Immunol. 2025-8-20

[2]
4D-printed microdevices for spatiotemporal detection of ctDNA and miRNA in pancreatic cancer: an in-depth review.

Med Oncol. 2025-9-3

[3]
ROSIE: AI generation of multiplex immunofluorescence staining from histopathology images.

Nat Commun. 2025-8-16

[4]
Immune infiltration and stromal heterogeneity in pancreatic cancer: A prognostic model guiding immunotherapy response.

Oncol Lett. 2025-7-29

[5]
Importance of landscape exploration and progress in molecular therapies and precision medicine for pancreatic ductal adenocarcinoma.

World J Gastrointest Oncol. 2025-7-15

[6]
Knowledge Discovery in Databases of Proteomics by Systems Modeling in Translational Research on Pancreatic Cancer.

Proteomes. 2025-5-29

[7]
Comprehensive assessment of disulfidptosis-related long non-coding RNA index as biomarkers for predicting clinical outcomes and immune microenvironment in pancreatic cancer.

Transl Cancer Res. 2025-5-30

[8]
Complete Response in Recurrent End-Stage Pancreatic Cancer After Combined Immune Cell Therapy of α-Galactosylceramide Dendritic Cell Vaccine Therapy, Wilms' Tumor 1 Dendritic Cell Vaccine and Natural Killer Cell Therapy.

Cureus. 2025-5-6

[9]
Inflammation, Immunosuppression, and Immunotherapy in Pancreatic Cancer-Where Are We Now?

Cancers (Basel). 2025-4-28

[10]
Phenotypic heterogeneity and tumor immune microenvironment directed therapeutic strategies in pancreatic ductal adenocarcinoma.

Front Immunol. 2025-3-31

本文引用的文献

[1]
Claudin18.2 bispecific T cell engager armed oncolytic virus enhances antitumor effects against pancreatic cancer.

Mol Ther Oncolytics. 2023-8-24

[2]
The role of epithelial-mesenchymal transition and autophagy in pancreatic ductal adenocarcinoma invasion.

Cell Death Dis. 2023-8-7

[3]
Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer.

Nature. 2023-6

[4]
Targeting Periostin Expression Makes Pancreatic Cancer Spheroids More Vulnerable to Natural Killer Cells.

Biomedicines. 2023-1-19

[5]
PLA2G2A cancer-associated fibroblasts mediate pancreatic cancer immune escape via impeding antitumor immune response of CD8 cytotoxic T cells.

Cancer Lett. 2023-4-1

[6]
Cancer statistics, 2023.

CA Cancer J Clin. 2023-1

[7]
Metastatic phenotype and immunosuppressive tumour microenvironment in pancreatic ductal adenocarcinoma: Key role of the urokinase plasminogen activator (PLAU).

Front Immunol. 2022

[8]
Pancreatic stellate cells exploit Wnt/β-catenin/TCF7-mediated glutamine metabolism to promote pancreatic cancer cells growth.

Cancer Lett. 2023-2-28

[9]
Epithelial to Mesenchymal Transition as Mechanism of Progression of Pancreatic Cancer: From Mice to Men.

Cancers (Basel). 2022-11-24

[10]
Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition.

EBioMedicine. 2022-12

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索